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Introduction: Screening enables the identification of type 2 diabetes mellitus (T2DM)   during 
its asymptomatic stage and therefore allows early intervention which may lead to fewer com-
plications and improve outcomes. A targeted screening program was carried out in a United 
Kingdom (UK) multiethnic population to identify those with abnormal glucose tolerance.
Methods: A sample of individuals aged 25–75 years (40–75 white European) with at least one risk 
factor for T2DM were invited for screening from 17 Leicestershire (UK) general practices or through a 
health awareness campaign. All participants received a 75 g oral glucose tolerance test, cardiovascular 
risk assessment, detailed medical and family histories and anthropometric measurements.
Results: In the 3,225 participants who were screened. 640 (20%) were found to have some form 
of abnormal glucose tolerance of whom 4% had T2DM, 3% impaired fasting glucose (IFG), 
10% impaired glucose   tolerance (IGT) and 3% both IFG and IGT. The odds of detecting IGT 
was approximately 60% greater (confounder-adjusted odds ratios [OR] 1.67 [1.22–2.29]) in the 
South Asian population.
Conclusions: Around one in five people who had targeted screening have IGT, IFG or T2DM, 
with a higher prevalence in those of South Asian origin. The prevalence of undetected T2DM 
is lower in South Asians compared to previously published studies and maybe due to increased 
awareness of this group being at high risk.
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Introduction
By 2025 an estimated 4.2 million adults in the United Kingdom (UK) will have type 2 dia-
betes mellitus (T2DM).1,2 If current clinical practice continues the majority of these cases 
will go undetected for many years, and over 50% will be destined to develop potentially 
devastating vascular co-morbidities.3–5 The implications of an emerging disease pandemic 
on this scale, affecting around 1 in 15 of the working population are almost unimaginable 
and present a major threat to future healthcare and economic prosperity.
Screening enables the identification of T2DM in the lag phase between the onset 
of latent hyperglycemia and clinical diagnosis. This approach simultaneously reduces 
exposure to the deleterious effects of glucose whilst providing an opportunity to per-
form population-level vascular risk assessments. Early data from the United   Kingdom 
Prospective Diabetes Study (UKPDS) supported this view by demonstrating an 
inverse relationship between fasting plasma glucose at diagnosis, and adverse clinical 
outcomes.6 Subsequent long-term follow-up of this cohort demonstrates that in fact 
many years of glucose lowering intervention are required to influence cardiovascular 
outcomes in T2DM again indicating earlier intervention maybe beneficial.7Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Recent large intervention trials have clearly   demonstrated 
that treatment of individuals with abnormal glucose regula-
tion with structured lifestyle or pharmacological   interventions 
may lead to fewer complications or even prevent T2DM.8–10 
Indeed, glucose thresholds for the development of athero-
sclerosis remain contentious but are likely to be signifi-
cantly lower than existing diagnostic cut-offs for T2DM.11 
Therefore, screening activity aimed primarily at preventing 
large vessel cardiovascular disease (CVD) should possibly 
include “pre-diabetes” (impaired glucose regulation) which 
World Health Organization (WHO) define as impaired fast-
ing glycemia (IFG) and impaired glucose tolerance (IGT) 
glucose categories.12
Despite clear theoretical advantages for earlier detection 
and intervention there is currently no systematic screening 
program for T2DM in the UK and no evidence that T2DM 
cases identified through screening have improved outcomes. 
As a result the National Screening Committee does not cur-
rently advocate universal screening for T2DM and instead 
recommend strategies targeting populations at “high-risk”.13 
Acknowledging this and the multi-factorial nature of cardio-
vascular risk in this population they have pursued a national 
agenda in producing a vascular check handbook incorporat-
ing screening advice and suggesting a T2DM assessment 
for individuals over 45 years of age, an elevated body mass 
index (BMI) or hypertension.14,15
Black and Minority Ethnic (BME) groups are at particu-
larly high risk of abnormal glucose tolerance and T2DM, with 
reported prevalence 2–6 times that of the background white 
European population.1,16–21 To be effective national screening 
programs must adequately represent these groups by adapting 
to their specific needs and identifying barriers to the detection 
of disease and delivery of care early.22 There is currently little 
data describing the likely consequences of targeted T2DM 
screening in BME UK populations. In particular the burden 
of unidentified cardiovascular risk and glucose dysregula-
tion is crucial to appropriate planning and implementation 
of screening programs in these populations.
The aims of the STAR (Screening Those At Risk) 
study were to describe the clinical characteristics and car-
diovascular risk factor profile of a multiethnic population 
screened for T2DM with a targeted oral glucose tolerance 
test (OGTT).
Methods
The STAR study was designed to identify the prevalence of 
glucose disorders including T2DM using a predetermined 
targeted strategy. This screening study was conducted 
in L  eicestershire with a population of over 950,000, 
  approximately one third of whom are resident in Leicester 
city, Leicestershire, United Kingdom. South Asians make 
up 24% of the population. Individuals aged 40–75 years 
inclusive (25–75 for South Asians, Afro-Caribbeans and other 
races due to the reported higher risk of T2DM), who had at 
least one recognized risk factor for diabetes (identified from 
general practice computer records) from 17 general practices 
across Leicestershire were invited to attend   screening. Indi-
viduals on the practice list and fulfilling the entry   criteria 
were sent a letter and information pack in English or a 
flyer in four languages (Gujarati, Hindi, Urdu and Punjabi) 
advising patients how to get details in their native language. 
Non respondants were sent a second letter. In addition people 
were recruited in an opportunistic fashion by canvassing at 
local retail centers during a health awareness campaign “Be 
a star campaign”.
Risk factors for inclusion into the study included a 
documented clinical history of coronary heart disease, 
hypertension, dyslipidemia, cerebrovascular disease or 
peripheral vascular disease (PVD), previous history of 
IGT, gestational diabetes, polycystic ovary syndrome in 
those with a body mass index (BMI) . 25 kg/m2, a first-
degree relative with T2DM or BMI . 25 kg/m2, and cur-
rent or ex smokers. Exclusion criteria were patients who 
were housebound, had a terminal illness or were already 
known to have diabetes. All patients provided written 
informed consent. The screening was conducted within 
the general practice, on a mobile screening unit or at one 
of the local hospitals. Ethical approval was obtained from 
the local ethics committee.
screening visit
All individuals attended after at least an eight-hour fast, 
and venous blood samples were taken for glucose, HbA1c 
lipids and renal function. A 75-g oral glucose tolerance test 
(OGTT) (388 mls Lucozade) was given and a venous blood 
sample taken after 120 minutes. HbA1c was analyzed using 
the   BIORAD Variant II HPLC system (DCCT aligned.) 
All samples were analyzed in the same laboratory using 
stable methodology standardized to external quality assur-
ance reference values. Further assessment included blood 
pressure, height and weight (BMI calculated) to a set of 
standard   operating procedures by a trained member of 
research staff. Maximum waist and hip measurements were 
taken. Early morning urinary albumin and creatinine levels 
were measured and the albumin:creatinine ratio   calculated. 
A ratio $ 2.5 mg/mmol in males and 3.5 mg/mmol in Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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females was taken as microalbuminuria. A twelve-lead 
electrocardiograph was performed and classified according to 
the Minnesota classification.23 All individuals were asked to 
self-complete an ethnicity (Census classification) and general 
health questionnaire. A qualified nurse obtained patients’ past 
medical and medication history.
Individuals found to have glucose results within the 
diabetes range, using the WHO 1998 criteria, were invited 
for a repeat OGTT.24 The diagnosis of T2DM was made on 
the agreement of two OGTTs. In the event of discordant 
OGTT results (eg, baseline T2DM followed by rescreen 
IFG/IGT) a diagnosis of “pre diabetes” (impaired glucose 
regulation) was made. Patients found to have diabetes 
were invited for a full clinical assessment and were seen 
by the same physician.
statistical analysis
Analyses were carried out using Stata software (version 11; 
Stata Corp, College Station, TX). Data are presented for 
the total screened group and also by ethnicity (white Euro-
pean versus South Asian). Statistical differences between 
ethnicities are given both unadjusted and adjusted for age. 
Odds ratios (OR) (95% confidence intervals [CI]) for the 
comparison of glucose   abnormalities by ethnic group are 
calculated using logistic regression adjusted for age and 
separately adjusted for age, sex, smoking status, BMI, 
waist, HbA1c, total cholesterol, low-density lipoprotein 
(LDL) and high-density lipoprotein (HDL) cholesterol. 
Results are presented as mean (SD) or as count and 
percentage. A P-value , 0.05 was considered statistically 
significant.
Results
3,225 participants with at least one risk factor aged between 
40–75 (25–75 for South Asians) attended for screening. 66% 
were of white European origin, with South Asians (mostly 
of Indian origin) accounting for 30%. The remaining 4% 
was made up of African, Caribbean, and Chinese origins. 
The mean age of the total screened population was 55 years 
(SD 11.2), with 46% being male.
clinical characteristics of screened 
cohort by ethnicity
Table 1 shows the characteristics of those who attended 
screening. There were substantial differences between the 
white   European and South Asian screened populations, 
irrespective of the differential age inclusion criteria. White 
Europeans had significantly higher waist circumference 
and BMI, and higher levels of total cholesterol. White 
  Europeans also had slightly higher levels of systolic and 
diastolic blood pressure, but differences in blood pressure 
were not maintained after adjustment for age. South Asians 
had significantly higher levels of HbA1c, 5.9% (0.8%) versus 
5.7% (0.6%), P , 0.0001, this remained significant after 
adjustment for age. Independent of age there were higher 
levels of both current and ex smokers in the white European 
group. There were also differences in the co-morbidity 
profile of the two ethnic groups (Table 2). White Europeans 
Table 1 Demographics and biomedical data of those screened
Total White European South Asian P-value Age adjusted  
P-value 3225 2138 (66.3) 963 (29.9)
Age 55.1 (11.2) 58.4 (9.7) 48.3 (11.1) ,0.0001 –
sex, male 1495 (46.4) 948 (44.3) 500 (51.9) ,0.0001 ,0.0001
ethnicity, We 2138 (66.3) – – – –
ethnicity, sA 963 (29.9) – – – –
ethnicity, Other 124 (3.8) – – – –
smoking, current 803 (24.9) 647 (30.3) 117 (12.2) ,0.0001 ,0.0001
smoking, ex 696 (21.6) 609 (28.5) 76 (7.9) ,0.0001 ,0.0001
Weight 77.5 (16.1) 79.6 (16.5) 72.4 (13.8) ,0.0001 ,0.0001
BMi 28.1 (5.1) 28.5 (5.3) 27.2 (4.7) ,0.0001 ,0.0001
Waist 95.1 (13.1) 96.1 (13.6) 93.0 (11.7) ,0.0001 0.004
systolic blood pressure 132.8 (20.7) 135.1 (20.8) 127.8 (19.8) ,0.0001 0.57
Diastolic blood pressure 80.0 (10.8) 80.3 (10.7) 79.3 (11.0) 0.02 0.68
HbA1c 5.8 (0.7) 5.7 (0.6) 5.9 (0.8) ,0.0001 ,0.0001
cholesterol 5.4 (1.0) 5.5 (1.1) 5.1 (0.9) ,0.0001 ,0.0001
LDL 3.3 (0.9) 3.4 (0.9) 3.2 (0.8) ,0.0001 ,0.0001
HDL 1.3 (0.5) 1.4 (0.4) 1.2 (0.6) ,0.0001 ,0.0001
Abbreviations: We, white european; sA, south Asian; BMi, body mass index; LDL, cholesterol, low-density lipoprotein; HDL, high-density lipoprotein.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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had significantly higher levels of coronary heart disease, 
hypertension, CVD and PVD; these differences were driven 
by the age disparity and were not statistically significant 
when adjusted for age. No difference was seen for previ-
ous history of IGT, gestational diabetes or polycystic ovary 
syndrome.
Prevalence of abnormal  
glucose tolerance
Of the 3,225 patients screened 640 (20%) were found to have 
abnormal glucose tolerance, 4% had T2DM, 3% impaired 
fasting glycemia (IFG) and 10% IGT and 3% had both IFG 
and IGT (Table 3). The prevalence of abnormal glucose toler-
ance varied by ethnic group. There was a greater prevalence 
for South Asians compared to white Europeans across all 
glucose classifications apart from IFG. For example South 
Asians had a 70% greater age adjusted odds of having IGT 
(OR = 1.71, 95% CI: 1.28–2.26; P , 0.0001), and a twofold 
greater odds of having both T2DM (OR = 2.05, 95% CI: 
1.35–3.12; P = 0.001) or any form of abnormal glucose tol-
erance (OR = 1.99, 95% CI: 1.61–2.45; P , 0.0001). When 
adjusted for all confounding factors significant differences 
between South Asians and white Europeans remained for 
IGT, IGT or IFG and IGT and/or IFG.
Discussion
One in five of those screened for T2DM through the nation-
ally recommended targeted approach have some form of 
abnormal glucose tolerance. White Europeans have a greater 
prevalence of traditional risk factors for T2DM and CVD 
compared to South Asians but this increased prevalence can 
mostly be explained by the difference in age inclusion criteria. 
Irrespective of a similar or in some cases lower risk profile a 
two fold greater prevalence of T2DM is seen in those from a 
South Asian origin. This suggests that there are risk factors 
for T2DM which we have not measured in this study which 
explain the difference seen in prevalence.
An age-adjusted OR for T2DM of 2.05 (95% CI: 
1.35–3.12) in predominantly Indian South Asians is similar 
to incident estimates from a larger UK primary care data set 
and the most recent health survey for England.25,26 Our study 
adds to the remarkable paucity of published data describing 
the burden of glucose dysregulation in migrant South Asian 
populations using the gold standard OGTT.16,17,27,28
It is clear that this approach identifies a significant 
burden of unidentified cardiovascular risk in both white 
European and South Asian UK populations. Lower rates 
of traditional cardiovascular-risk factors (blood pres-
sure, smoking, dyslipidemia, BMI) emphasizes the likely 
Table 2 co-morbidities of those screened
Total White European South Asian P-value Age adjusted  
P-value 3225 2138 (66.3) 963 (29.9)
Known history cHD 415 (12.9) 328 (15.3) 82 (8.5) ,0.0001 0.29
Hypertension 1294 (40.1) 965 (45.1) 282 (29.3) ,0.0001 0.17
cerebrovascular disease or peripheral 
vascular disease
91 (2.8) 75 (3.5) 13 (1.4) 0.001 0.62
impaired glucose tolerance  47 (1.5) 33 (1.5) 14 (1.5) 0.85 0.73
Gestational diabetes  57 (1.8) 37 (1.7) 19 (2.0) 0.64 0.14
Polycystic ovary syndrome 8 (0.3) 6 (0.3) 2 (0.2) 0.71 0.09
Abbreviation: cHD, coronary heart disease.
Table 3 Prevalence of type 2 diabetes and impaired glucose regulation. The odds ratios (OR) in bold are statistically significant
Total White European South Asian P value Age adjusted OR SA 
versus WE
Fully adjusted OR SA 
versus WE*
iFG 91 (2.8) 55 (2.6) 30 (3.1) 0.39 1.48 (0.90 to 2.44) 1.56 (0.90 to 2.68)
iGT 315 (9.8) 209 (9.8) 96 (10.0) 0.86 1.71 (1.28 to 2.26) 1.67 (1.22 to 2.29)
iGT or iFG 406 (12.6) 264 (12.4) 126 (13.1) 0.57 1.70 (1.32 to 2.19) 1.67 (1.26 to 2.23)
iGT and iFG 111 (3.4) 68 (3.2) 41 (4.3) 0.13 1.74 (1.13 to 2.69) 1.44 (0.88 to 2.34)
iGT and/or iFG 517 (16.0) 332 (15.5) 167 (17.3) 0.20 1.79 (1.42 to 2.25) 1.62 (1.25 to 2.10)
T2DM 123 (3.8) 74 (3.5) 44 (4.5) 0.12 2.05 (1.35 to 3.12) 0.66 (0.34 to 1.28)
Abnormal glucose 640 (19.8) 406 (19.0) 211 (21.9) 0.04 1.99 (1.61 to 2.45) 1.24 (0.95 to 1.62)
Notes: *Adjusted for age, sex, smoking status, BMi, waist, HbA1c, total cholesterol, LDL, HDL.
Abbreviations: OR, odds ratios; sA, south Asian; We, white european; iFG, impaired fasting glycemia; iGT, impaired glucose tolerance; T2DM, type 2 diabetes mellitus; 
BMi, body mass index; LDL, low-density lipoprotein; HDL, high-density lipoprotein.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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importance of glucose disorders, insulin resistance and 
other unknown contributors to premature vascular disease 
in British South Asians.
The significantly increased prevalence of IGT in south 
Asians after adjustment for confounders also suggests that 
two-hour glucose levels are important and therefore, although 
cumbersome and impractical, the OGTT should be used in the 
screening of these at risk individuals. The utility of measuring 
HbA1c% or alternative glucose indices to estimate two hour 
glucose levels in this population is unknown and requires further 
investigation.
Individuals were recruited into this study if they had one 
or more risk factors for T2DM in line with recommendations 
of the UK National Screening Committee.13 These results 
are therefore highly applicable to multiethnic screening 
programs. An additional strength of this study is that all 
participants received an OGTT and the diagnosis of T2DM 
was made on the basis of a repeat OGTT. This is a unique and 
extremely important aspect of STAR as the clinical relevance 
of glucose intolerance in the patho physiology and prevention 
of T2DM becomes more apparent especially in populations 
predisposed to central obesity. A large cohort of people were 
screened (. 2000) including a significant proportion of South 
Asians. Although there is some heterogeneity among the 
South Asian population in Leicester, the majority of those 
included were of Indian origin.
Conclusion
Earlier identification of dysglycemia may be an effective 
method of improving vascular outcomes in people with 
T2DM. Economic modeling suggests targeted population 
screening for T2DM may be cost effective.29 Results of these 
studies may not be directly applicable to ethnic minority 
populations at risk of T2DM and data describing unidenti-
fied cardiovascular risk in these groups is urgently needed. 
We have described the methodology and characteristics of 
a large scale targeted screening program for T2DM. The 
prevalence of unidentified abnormal glucose tolerance is 
high, particularly within the South Asian ethnic minority.
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